Ingavirin® (Ingavirin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceImidazolylethanamide of pentanedioic acidImidazolylethanamide of pentanedioic acid
Similar drugsTo uncover
  • Ingavirin®
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Ingavirin®
    capsules inwards 
    VALENTA PHARM, PAO     Russia
    • Dosage form: & nbspcapsules
    Composition:One capsule contains: Active substance: Imidazolylgannamide pentanedioic acid (vitaglutam) in terms of 100% substance -30.0 mg / 90.0 mg Excipients: lactose monohydrate - 100.0 mg / 90.0 mg, potato starch - 46, 0 mg / 36.0 mg, silicon dioxide colloid (aerosil) 2.0 mg / 2.0 mg, magnesium stearate 2.0 mg / 2.0 mg. The composition of the capsule shell: For the dosage of 30 mg - titanium dioxide E 171 -2.0000%, the colorant diamond black E 151 - 0.1533%, the dye blue patented E 131 - 0.1314%, the dye crimson [Ponso 4R] E 124 - 0, 0192%, dye azorubin Е 122 - 0,0821%, gelatin - up to 100%. For the dosage of 90 mg titanium dioxide E 171 -1.33333%, the dye crimson [Ponso 4R] E 124 - 0.0008%, the dye azorubin E 122-0.3066%, the dye quinoline yellow E 104-0.4207%, gelatin - up to 100%. Ink composition for the logo: shellac, ripo-pilen glycol E 1520, titanium dioxide E 171.
    Description:Capsules number 2 in blue (for dosage of 30 mg), capsule No. 2 in red (for a dosage of 90 mg). The cap of the capsule has a white logo in the form of a ring and the letter AND inside the ring. The contents of the capsules are granules and white or almost white powder; conglomerates can be formed, easily crumbling with slight pressure.
    Pharmacotherapeutic group:antiviral and immunostimulating agent
    ATX: & nbsp

    J.05.A.X   Other antiviral drugs

    V.03.A.F   Drugs that reduce the toxicity of cytostatic therapy

    Pharmacodynamics:
    Antiviral drug. In preclinical and clinical studies, the effectiveness of Ingavirin® against influenza A (A (H1N1)) viruses, including "pig" A (I-IlNl) pdm09, A (M3N2), A (H5N1), and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in pre-clinical studies: coronavirus, metapneumovirus, enteroviruses, including the Coxsackie virus and riiovirus. Ingavirin ® helps to accelerate the elimination of viruses, reduce the duration of the disease, reduce the risk of complications. The mechanism of action is realized at the level of infected cells due to stimulation of the factors of innate immunity, suppressed by viral proteins. In experimental studies, in particular, it was shown that the Ingavirin® preparation increases the expression of IFNAR-1 interferon receptor on the surface of epithelial and immunocompetent cells. An increase in the density of interferon-new receptors leads to an increase in the sensitivity of cells to the signals of endogenous interferon.The process is accompanied by the activation (phosphorylation) of the transmitting protein STAT1, which transmits the signal to the nucleus of the cell to induce antiviral genes. It is shown that under the conditions of infection, the drug stimulates the production of the antiviral effector protein MxA, and inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing the process of viral replication.
    The drug Iigavirin® causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced alpha-interferon producing capacity of the blood leukocytes, stimulates the y-interferon producing capacity of leukocytes. Causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells, which have a high killer activity in relation to virus-infected cells.
    The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (TNF-a, IL-1 (3 and IL-6)), decreased myeloperoxidase activity. the effectiveness of therapy on the model of bacterial sepsis, including those caused by penicillin-resistant strains of staphylococcus.The conducted experimental toxicological studies indicate a low level of toxicity and a high profile of the drug safety. In terms of acute toxicity, Ingavirin ® belongs to the 4th toxicity class - "Malotoxic substances" (when determining LD50 in acute toxicity experiments, it was not possible to determine the lethal dose of the drug).

    Pharmacokinetics:Suction and distribution
    In recommended doses, the determination of the drug in blood plasma by available techniques is not possible.
    In an experiment using a radioactive label, it was found that the drug quickly enters the blood from the gastrointestinal tract. Evenly distributed to internal organs. Maximum concentrations in the blood, blood plasma and most organs are reached 30 minutes after the administration of the drug. The values ​​of AUC (the area under the pharmacokinetic concentration-time curve) of the kidneys, liver and lungs slightly exceed the blood AUC (43.77 μg.h / g). The AUC values ​​for the spleen, adrenal glands, lymph nodes and thymus are lower than the blood AUC. MRT (average retention time) in the blood - 37.2 hours.
    At a 5-day course of oral intake of the drug once a day, it accumulates in the internal organs and tissues. At the same time, the qualitative characteristics of the pharmacokinetic curves after each administration of the drug were identical: a rapid increase in the drug concentration after each administration and then a slow decrease by 24 hours.
    Metabolism.
    The drug is not metabolized in the body and is excreted unchanged.
    Excretion.
    The main elimination process takes place within 24 hours. During this period 80% of the administered dose is withdrawn: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 hours. Of these, 77% are excreted through the intestine and 23% through the kidneys.
    Indications:
    Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory-no-syncytial infection) in adults and children from 13 years of age.
    Prevention of influenza A and B and other acute respiratory viral infections in adults.
    Contraindications:
    Individual intolerance to the components of the drug.
    Deficiency of lactase, lactose intolerance, glucose-galactose malabsorption. Pregnancy.
    Children under the age of 13 years for indication of "treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection)." Children under 18 years of age for indication of "prevention of influenza A and B and other acute respiratory viral infections."
    Pregnancy and lactation:
    The use of the drug during pregnancy has not been studied.
    The use of the drug during lactation has not been studied, so if you need to use the drug during lactation should stop breastfeeding.
    Dosing and Administration:
    Inside. Regardless of food intake. To treat influenza and acute respiratory viral infections, adults are prescribed 90 mg once a day, children from 13 to 17 years - 60 mg once a day.

    Duration of treatment is 5-7 days (depending on the severity of the condition). Acceptance of the drug begins with the appearance of the first symptoms of the disease, preferably no later than 2 days from the onset of the disease. To prevent influenza and acute respiratory viral infections after contact with sick persons, adults are prescribed 90 mg once a day for 7 days.
    Side effects:Allergic reactions (rarely).
    Overdose:Cases of drug overdose are not described.
    Interaction:There were no cases of interaction of Ingavirin® with other medications.
    Special instructions:
    The drug does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in persons of various professions, including. requiring increased attention and coordination of movements.
    It is not recommended to take other antiviral drugs at the same time.
    Form release / dosage:Capsules, 30 mg and 90 mg
    Packaging:For 7 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered. 1 or 2 contiguous cell packs (for a dosage of 30 mg), or 1 circuit cell package (for a dosage of 90 mg), together with the instruction for use, is placed in a pack.
    Storage conditions:
    In the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-006330/08
    Date of registration:07.08.2008
    The owner of the registration certificate:VALENTA PHARM, PAO VALENTA PHARM, PAO Russia
    Manufacturer: & nbsp
    Representation: & nbspVALENTA PHARM, PAO VALENTA PHARM, PAO Russia
    Information update date: & nbsp27.05.2015
    Illustrated instructions
      Instructions
      Up